NCT04341129View on ClinicalTrials.gov

Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 13, 2020

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
Breast NeoplasmsBreast DiseasesBreast FibroadenomaBreast Cancer
Interventions
DRUG

Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine)

To test the diagnostic effectiveness of an abbreviated MRI to a full MRI in the evaluation of breast lesions using Dotarem

Trial Locations (1)

60637

University of Chicago Medicine, Chicago

Sponsors

Collaborators (1)

Guerbet
All Listed Sponsors
collaborator

Guerbet

INDUSTRY

lead

University of Chicago

OTHER

NCT04341129 - Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine) | Biotech Hunter | Biotech Hunter